# A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD

> **NCT01192191** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 187 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg
- **DRUG:** Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg

## Key facts

- **NCT ID:** NCT01192191
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2017-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01192191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01192191, "A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01192191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*